Ask AI

Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care

Gain global expert insights into PI3K/AKT/mTOR pathway inhibitor use in the management of HR+/HER2- metastatic breast cancer to optimize patient outcomes and minimize therapy-related toxicities, through commentaries, podcasts, Interactive Case Challenges, an Interactive Decision Support Tool, and a downloadable infographic.

Share

Program Content

Activities

PI3K/AKT Inhibitors in mBC
Novel Targeted Therapies for PIK3CA/AKT1/PTEN-Altered Metastatic Breast Cancer: Key Evidence and Real-world Insights to Optimize Patient Care
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: September 29, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from F. Hoffmann-La Roche Ltd.

F. Hoffmann-La Roche Ltd.